Comparison of impact of primary percutaneous transluminal coronary angioplasty and primary stenting on short-term mortality in patients with cardiogenic shock and evaluation of prognostic determinants

Abstract

sestamibi in patients undergoing cardiac transplantation. A scintigraphic/pathological study. Circulation 1996;94:1010–1017. 9. Maes AF, Borgers M, Flameng W, Nuyts JL, van de Werf F, Ausma JJ, Sergeant P, Mortelmans LA. Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT. Correlation with histologic and positron emission tomographic studies and functional followup. J Am Coll Cardiol 1997;29:62–68. 10. Dakik HA, Howell JF, Lawrie GM, Espada R, Weilbaecher DG, He ZX, Mahmarian JJ, Verani MS. Assessment of myocardial viability with 99m Tcsestamibi tomography before coronary bypass graft surgery: correlation with histopathology and postoperative improvement in cardiac function. Circulation 1997;96:2892–2898. 11. Miller TD, Christian TF, Hopfenspirger MR, Hodge DO, Gersh BJ, Gibbons RJ. Infarct size after acute myocardial infarction measured by quantitative tomographic 99m Tc sestamibi imaging predicts subsequent mortality. Circulation 1995;92:334–341. 12. Miller TD, Hodge DO, Sutton JM, Grines CL, O’Keefe JH, DeWood MA, Okada RD, Fletcher WO Jr, Gibbons RJ. Usefulness of technetium-99m sestamibi infarct size in predicting posthospital mortality following acute myocardial infarction. Am J Cardiol 1998;81:1491–1493. 13. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Inmediate angioplasty compared with the administration of a thrombolytic agent followed by a conservative treatment for myocardial infarction. N Engl J Med 1993;328:685–691. 14. O’Keefe JH, Grines CL, DeWood MA, Schaer GL, Browne K, Magorien RD, Kalbfleisch JM, Fletcher WO Jr, Bateman TM, Gibbons RJ. Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996;78:747–750. 15. Collaborative Organization for RheothRx Evaluation (CORE). Effects of RheothRX on mortality, morbidity, left ventricular function and infarct size in patients with acute myocardial infarction. Circulation 1997;96:192–201. 16. Anglo Scandinavian Study of Early Thrombolysis Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 2:525–530. 17. Christian TF, Gibbons RJ, Gersh BJ. Effect of infarction location on myocardial salvage assessed by technetium-99m isonitrile. J Am Coll Cardiol. 1991; 17:1303–1308. 18. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl Med 1993;329:1615–1622. 19. Galli M, Marcassa C, Bolli R, Giannuzzi P, Temporelli PL, Imparato A, Silva Orrego PL, Giubbini R, Giordano A, Tavazzi L. Spontaneous delayed recovery of perfusion and contraction after the first 5 weeks after anterior infarction. Evidence for the presence of hibernating myocardium in the infarcted area. Circulation 1994;90:1386–1397.